Albert Lowe
Stock Analyst at Craig-Hallum
(3.39)
# 2,118
Out of 4,402 analysts
132
Total ratings
38.5%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Downgraded: Hold | $2 | $1.59 | +25.79% | 13 | Jun 4, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $29.00 | +124.14% | 6 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $25 → $12 | $1.99 | +503.02% | 9 | May 12, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | n/a | $2.01 | - | 6 | May 6, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.52 | $8.42 | +131.88% | 12 | May 5, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $140 | $48.93 | +186.12% | 1 | Apr 27, 2026 | |
| SABS SAB Biotherapeutics | Maintained: Buy | n/a | $3.38 | - | 9 | Apr 22, 2026 | |
| IRD Opus Genetics | Maintained: Buy | n/a | $3.91 | - | 9 | Apr 14, 2026 | |
| RMNI Rimini Street | Maintained: Buy | n/a | $4.17 | - | 1 | Apr 2, 2026 | |
| PVLA Palvella Therapeutics | Maintained: Buy | n/a | $106.38 | - | 5 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.7995 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $3.86 | +3.63% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.59 | +286.85% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.57 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $14.09 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.28 | +134.38% | 7 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.09 | +266.97% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.27 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $363.58 | n/a | 1 | Jun 4, 2024 |
Cardiff Oncology
Jun 4, 2026
Downgraded: Hold
Price Target: $2
Current: $1.59
Upside: +25.79%
Neurogene
May 15, 2026
Maintained: Buy
Price Target: $65
Current: $29.00
Upside: +124.14%
Actuate Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $25 → $12
Current: $1.99
Upside: +503.02%
Compass Therapeutics
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $2.01
Upside: -
Eupraxia Pharmaceuticals Inc.
May 5, 2026
Reiterated: Buy
Price Target: $19.52
Current: $8.42
Upside: +131.88%
Spruce Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $140
Current: $48.93
Upside: +186.12%
SAB Biotherapeutics
Apr 22, 2026
Maintained: Buy
Price Target: n/a
Current: $3.38
Upside: -
Opus Genetics
Apr 14, 2026
Maintained: Buy
Price Target: n/a
Current: $3.91
Upside: -
Rimini Street
Apr 2, 2026
Maintained: Buy
Price Target: n/a
Current: $4.17
Upside: -
Palvella Therapeutics
Mar 19, 2026
Maintained: Buy
Price Target: n/a
Current: $106.38
Upside: -
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $0.7995
Upside: -
Feb 17, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $3.86
Upside: +3.63%
Feb 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.59
Upside: +286.85%
Jan 23, 2026
Maintained: Buy
Price Target: n/a
Current: $3.57
Upside: -
Jan 12, 2026
Maintained: Buy
Price Target: n/a
Current: $14.09
Upside: -
Nov 25, 2025
Reiterated: Buy
Price Target: $3
Current: $1.28
Upside: +134.38%
Nov 13, 2025
Maintained: Buy
Price Target: $4
Current: $1.09
Upside: +266.97%
Jun 6, 2024
Maintained: Buy
Price Target: n/a
Current: $10.27
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $363.58
Upside: n/a